Bonum Therapeutics
Nina Kondza has a diverse work experience that spans several industries. Nina most recently worked as a Lab Manager at Bonum Therapeutics since August 2022. Prior to that, they held the same position at Good Therapeutics, Inc. from March 2022 until August 2022. Before transitioning to lab management roles, Nina worked as an Associate Lab Manager, Scientific Operations at Zymeworks Inc. from July 2021 to March 2022, where they oversaw the build-out of a new laboratory and managed inventory.
From May 2019 to July 2021, Nina worked at the Allen Institute for Immunology in two different roles. First, they served as a Lab Operations Coordinator II from May 2021 to July 2021, followed by a role as a Research Associate from May 2019 to May 2021.
Prior to their scientific work, Nina gained administrative experience as a Residential Operations Administrator at John L. Scott Real Estate from March 2018 to February 2019. Nina also worked as a Floor Lead, Visual Merchandising at Sur La Table from October 2015 to July 2017, where they directed employees, resolved customer issues, and supported sales initiatives.
Nina began their professional journey as a Student Assistant at the Fang Lab, Department of Microbiology, University of Washington from April 2014 to October 2015. In this role, they were responsible for equipment maintenance, trained new assistants, and implemented organizational schemes to improve lab efficiency.
Nina Kondza pursued their education in the field of Bioengineering and Biomedical Engineering. From 2012 to 2013, they attended UC San Diego. Though their degree name during this period is not provided, it can be assumed that they completed coursework in their chosen field. Nina then went on to study at the University of Washington from 2014 to 2017, where they earned a Bachelor of Science (B.S.) degree in Bioengineering and Biomedical Engineering.
This person is not in any teams
Bonum Therapeutics
Bonum Therapeutics is creating a technology platform that can be used to treat a wide range of diseases, including cancer which is the company’s primary therapeutic area of focus—as well as metabolic diseases, immunology, and pain management.